Expert Ratings For ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
13 analysts have provided mixed ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target is $28.46, with a high of $37.00 and a low of $19.00. Recent ratings show a slight decline in the average price target by 3.13%. Key analysts have maintained or lowered their ratings and price targets, reflecting varied sentiments about the company's future performance.
June 25, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
13 analysts have provided mixed ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target is $28.46, with a high of $37.00 and a low of $19.00. Recent ratings show a slight decline in the average price target by 3.13%.
The mixed ratings and slight decline in the average price target suggest a neutral short-term impact on ACADIA Pharmaceuticals' stock price. While some analysts maintain bullish positions, others have lowered their ratings and price targets, indicating uncertainty about the company's near-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100